异二醇用于揭示静止导电和非肺静脉触发器在心房移除期间:前性多中心研究
Saumil R Oza1, Daniela Hincapie2,3, Manasvi Gupta4
1Ascension St. Vincent's Cardiology, Jacksonville, Florida, USA.
Journal of cardiovascular electrophysiology
|July 14, 2025
概括
在放射频导管切除中用于 Paroxysmal 心房动时使用异二醇并没有改善长期结果. 这项研究发现,它增加了手术时间,但没有增强对心房律乱的免费性.
科学领域:
- 电力生理学 电力生理学
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
背景情况:
- 射频导管切除 (RFCA) 后心房的复发通常是由于肺静脉重新连接或非肺静脉触发因素.
- 异二醇在揭示静止传导和非肺静脉触发器的实用性在RFCA期间用于心房仍然受到争议.
研究的目的:
- 评估异二醇在确定休眠导电和非肺静脉触发器的有效性,在RFCA期间对帕洛西斯马耳动脉动 (PAF) 进行评估.
- 评估异二醇对手术结果和PAF的RFCA后的长期临床成功的影响.
主要方法:
- 来自REAL-AF注册表的前性多中心队列研究包括接受PAFRFCA的患者.
- 患者接受了异二醇或没有干预,并在12个月后进行随访,以评估没有心房失常.
- 关键结果包括程序持续时间,首次通过肺静脉隔离率和长期心律失常复发.
主要成果:
- 异二醇在10.2%的患者中发现了休眠导电或非肺静脉触发器.
- 异二醇使用与更长的手术时间 (p=0.002) 和降低第一通肺静脉隔离率 (p=0.007) 相相关.
- 在12个月后,在异二醇和对照组之间没有观察到无心房律乱的显著差异 (p=0.4).
结论:
- 在PAF的RFCA期间服用异二醇会增加程序复杂性和废除程度.
- 在这种情况下使用异二醇并没有导致改善临床结果或减少12个月的随访期间心律失常的复发.
- 目前的证据表明,异二醇可能对改善 Paroxysmal 心房的 RFCA 疗效没有好处.
相关概念视频
Cardiopulmonary Resuscitation IV: Pharmacological Management
80
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
80
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.2K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.2K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
861
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
861
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
168
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
168
Cardiopulmonary Resuscitation III: AED Use
72
Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
72
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
1000
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1000


